Positive Press Coverage Somewhat Unlikely to Affect Seres Therapeutics (MCRB) Stock Price

News coverage about Seres Therapeutics (NASDAQ:MCRB) has been trending positive on Wednesday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Seres Therapeutics earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.6062261016028 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

Several equities research analysts recently weighed in on the company. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. BidaskClub raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $18.00.

Shares of Seres Therapeutics (MCRB) opened at $9.14 on Wednesday. Seres Therapeutics has a 12 month low of $7.90 and a 12 month high of $17.42. The company has a market capitalization of $374.37, a price-to-earnings ratio of -4.15 and a beta of 0.28. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.15.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. The firm had revenue of $3.06 million for the quarter, compared to analysts’ expectations of $3.00 million. equities research analysts anticipate that Seres Therapeutics will post -2.65 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Positive Press Coverage Somewhat Unlikely to Affect Seres Therapeutics (MCRB) Stock Price” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.themarketsdaily.com/2018/03/14/positive-press-coverage-somewhat-unlikely-to-affect-seres-therapeutics-mcrb-stock-price.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply